AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16218176 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 200
Study 12117728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 70 mg transdermally daily
Number of subjects: 53
Study 12117728 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (rhCG) 250 microg twice weekly
Number of subjects: 53
Study 12117728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both DHT and rhCG studies)
Number of subjects: 53
Study 10201608 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft transplantation
Number of subjects: 81
Study 10201608 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C with conjunctival flap
Number of subjects: 81
Study 7776454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ileal ureter (group 2)
Number of subjects: 50
Study 7776454 — intervention group
Group type: COMPARATOR
Intervention: Standard ileal ureter (group 1)
Number of subjects: 50
Study 7776454 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of renal function between group 1 and group 2 (without reflux)
Number of subjects: 50
Study 2104071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50
Study 2104071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 388053 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) treatment, 2 units of TF administered subcutaneously on days 1 and 15
Number of subjects: 13
Study 388053 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 13
Study 388053 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) treatment
Number of subjects: 13
Study 31479138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR target 1.8)
Number of subjects: 1650
Study 31479138 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity warfarin (INR target 2.5)
Number of subjects: 1650
Study 27484766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aidi intravenous injection plus NP regimen (2 cycles)
Number of subjects: 150
Study 27484766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aidi intratumor injection plus NP regimen (2 cycles)
Number of subjects: 150
Study 27484766 — intervention group
Group type: COMPARATOR
Intervention: Control group (NP regimen only)
Number of subjects: 150
Study 25933151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine HCl + 1/200,000 epinephrine (10 mL)
Number of subjects: 91
Study 25933151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine HCl + 1/200,000 epinephrine (10 mL)
Number of subjects: 91
Study 25933151 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (10 mL)
Number of subjects: 91
Study 24130124 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable RBD
Number of subjects: 42
Study 21504955 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk exercises on physio ball
Number of subjects: 30
Study 21504955 — intervention group
Group type: COMPARATOR
Intervention: Trunk exercises on plinth (Control)
Number of subjects: 30
Study 19732673 — intervention group
Group type: EXPERIMENTAL
Intervention: Precomprehensive orthodontic treatment
Number of subjects: 293
Study 19732673 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinterceptive orthodontic treatment
Number of subjects: 293
Study 19732673 — intervention group
Group type: COMPARATOR
Intervention: Nonorthodontic comparison
Number of subjects: 293
Study 19732673 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall and oral health QoL
Number of subjects: 293
Study 17690795 — intervention group
Group type: EXPERIMENTAL
Intervention: Random alcohol testing
Number of subjects: 0
Study 17690795 — intervention group
Group type: COMPARATOR
Intervention: Control group (light passenger vehicle drivers)
Number of subjects: 0
Study 15183620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone (CD)
Number of subjects: 1850
Study 15183620 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1850
Study 11600590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 11
Study 11600590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin
Number of subjects: 11
Study 11600590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9732919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradicating treatment (Group 1)
Number of subjects: 20
Study 9732919 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 20
Study 9732919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradicating treatment (Group 2 after initial follow-up)
Number of subjects: 20
Study 8277068 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (15 IU/kg body weight per h) with aspirin
Number of subjects: 250
Study 8277068 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 250
Study 3057817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 81
Study 3057817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 81
Study 3057817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 30927707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 59
Study 30927707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29390463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 100
Study 29390463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25445732 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 20
Study 25445732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 20
Study 25445732 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical matched cases)
Number of subjects: 20
Study 23895505 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1 g twice daily
Number of subjects: 904
Study 23895505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 904
Study 23895505 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and Aspirin combination
Number of subjects: 904
Study 23895505 — intervention group
Group type: COMPARATOR
Intervention: Placebo for EPA
Number of subjects: 904
Study 23895505 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Aspirin
Number of subjects: 904
Study 20880282 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding daily to satiation (FD)
Number of subjects: 264
Study 20880282 — intervention group
Group type: COMPARATOR
Intervention: No feed for 3 days, then feeding the same amount offered to the control groups for the next 3 days (NF/R controlled)
Number of subjects: 264
Study 20880282 — intervention group
Group type: EXPERIMENTAL
Intervention: No feed for 3 days, then feeding to apparent satiation for the next 3 days (NF/R at satiation)
Number of subjects: 264
Study 20880282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and refeeding (both NF/R controlled and NF/R at satiation)
Number of subjects: 264
Study 18997622 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboaspiration followed by stenting (Group I, 19 patients)
Number of subjects: 42
Study 18997622 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone (Group II, 23 patients)
Number of subjects: 42
Study 16894077 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Steps for Young Children program (HS) with prenatal component
Number of subjects: 439
Study 16894077 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Steps for Young Children program (HS) without prenatal component
Number of subjects: 439
Study 16894077 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 439
Study 15479360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole 30 mg
Number of subjects: 87
Study 15479360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lansoprazole 30 mg
Number of subjects: 87
Study 15479360 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 87
Study 11340101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats diet (45 g/(4.2 MJ dietary energy. d), n = 22)
Number of subjects: 43
Study 11340101 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 21)
Number of subjects: 43
Study 11340101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats diet
Number of subjects: 43
Study 11340101 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 43
Study 9499103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy
Number of subjects: 10
Study 8002763 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise program
Number of subjects: 44
Study 8002763 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (control group)
Number of subjects: 44
Study 2530541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime alone
Number of subjects: 8
Study 2530541 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox followed 30 min later by cefixime
Number of subjects: 8
Study 2530541 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox followed 4 hours later by cefixime
Number of subjects: 8
Study 2530541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alka-Seltzer followed 30 min later by cefixime
Number of subjects: 8
Study 1240869 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric‐training Group (ITG)
Number of subjects: 52
Study 1240869 — intervention group
Group type: COMPARATOR
Intervention: Control‐exercise Group (CEG)
Number of subjects: 52
Study 29485319 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness meditation intervention
Number of subjects: 139
Study 29485319 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational (active control) group
Number of subjects: 139
Study 28492476 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimble GreenSeeker® (TGS) and Holland Scientific Crop Circle™ ACS‐430 (HCCACS‐430) sensors used to predict potato yield before the second hilling (6‐8 leaf stage)
Number of subjects: 2
Study 28492476 — intervention group
Group type: EXPERIMENTAL
Intervention: Holland Scientific Crop Circle™ ACS‐430 (HCCACS‐430) sensor
Number of subjects: 2
Study 28492476 — intervention group
Group type: EXPERIMENTAL
Intervention: Weather data (precipitation variations)
Number of subjects: 2
Study 26080338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous ertapenem 1 g/d for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Number of subjects: 530
Study 26080338 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (standard open appendectomy)
Number of subjects: 530
Study 26080338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 530
Study 23848326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost simulated obstetrical emergencies (PPH or PEC) followed by debriefing
Number of subjects: 20
Study 23848326 — intervention group
Group type: COMPARATOR
Intervention: Lecture on PPH or PEC
Number of subjects: 20
Study 22008822 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 toddler dose
Number of subjects: 0
Study 20107684 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage mixed with 25 g of rapadura and 40 mg of ascorbic acid (per 200-mL serving)
Number of subjects: 0
Study 20107684 — intervention group
Group type: COMPARATOR
Intervention: Beverage sweetened with 25 g of standard refined sugar and 40 mg of ascorbic acid (per 200-mL serving)
Number of subjects: 0
Study 16437248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin
Number of subjects: 52
Study 16437248 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin instillation
Number of subjects: 52
Study 16437248 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDA
Number of subjects: 52
Study 15639694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/d
Number of subjects: 1024
Study 15639694 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 1024
Study 15546223 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (20 min a day for 3 days)
Number of subjects: 104
Study 15546223 — intervention group
Group type: COMPARATOR
Intervention: Nonemotional topic writing (control group)
Number of subjects: 104
Study 11005269 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 6 months
Number of subjects: 31
Study 11005269 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 12 months
Number of subjects: 31
Study 11005269 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 31
Study 11005269 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 31
Study 8938539 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-negative blood transfusion
Number of subjects: 41
Study 1603340 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitol
Number of subjects: 40
Study 1603340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol
Number of subjects: 40
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr‐EDTA
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐rhamnose
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐400
Number of subjects: 0
Study 3086024 — intervention group
Group type: COMPARATOR
Intervention: Cetrimide and hyperosmolar stress
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose and 51Cr‐EDTA
Number of subjects: 0
Study 3419838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (US) at 0.1 W/cm2
Number of subjects: 125
Study 3419838 — intervention group
Group type: COMPARATOR
Intervention: 'Mock' US with massage
Number of subjects: 125
Study 3419838 — intervention group
Group type: COMPARATOR
Intervention: 'Mock' US without massage
Number of subjects: 125
Study 3419838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-massage with a dummy applicator
Number of subjects: 125
Study 3419838 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 125
Study 30817467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 30817467 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 27554689 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-high 30-40 mm Hg compression therapy for 7 days
Number of subjects: 70
Study 27554689 — intervention group
Group type: COMPARATOR
Intervention: No compression therapy
Number of subjects: 70
Study 25743602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dancesport training program (16 weeks, 32 hours total)
Number of subjects: 686
Study 23883571 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric IV nutrition (50% of measured energy expenditure)
Number of subjects: 16
Study 23883571 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric IV nutrition (100% of measured energy expenditure)
Number of subjects: 16
Study 21310898 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 91
Study 21310898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical therapy)
Number of subjects: 91
Study 19930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbance and fatigue severity
Number of subjects: 20
Study 19930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy measurements
Number of subjects: 20
Study 19930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported depressive symptoms
Number of subjects: 20
Study 19930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Outcomes Short Form-36, version 2
Number of subjects: 20
Study 17485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from moderate disability (mRS 3)
Number of subjects: 1662
Study 17485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from severe disability (mRS 4)
Number of subjects: 1662
Study 17485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from very severe disability (mRS 5)
Number of subjects: 1662
Study 17485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recovery from disability (mRS > or = 3)
Number of subjects: 1662
Study 17485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of recovery
Number of subjects: 1662
Study 16213869 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen alone or combined with medroxyprogesterone acetate
Number of subjects: 0
Study 16213869 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (dosage not specified)
Number of subjects: 0
Study 11570651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on social‐cognitive theory to reduce sexual HIV risk behaviors
Number of subjects: 3706
Study 11570651 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3706
Study 11570651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 3706
Study 10181028 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Group (IG) with self-report and weight measurement + six body weighing habit items
Number of subjects: 223
Study 10181028 — intervention group
Group type: COMPARATOR
Intervention: Uninformed Group (UG) with self-report and weight measurement + one body weight item
Number of subjects: 223
Study 10181028 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Group (IG)
Number of subjects: 223
Study 10181028 — intervention group
Group type: COMPARATOR
Intervention: Uninformed Group (UG)
Number of subjects: 223
Study 7848946 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter with a terminal hole
Number of subjects: 200
Study 7848946 — intervention group
Group type: COMPARATOR
Intervention: Catheter with three lateral eyes
Number of subjects: 200
Study 3389864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone, 2.5 mg per day (mean dose 0.072 mg/kg/day)
Number of subjects: 19
Study 3389864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3389864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone, 2.5 mg per day (mean dose 0.073 mg/kg/day) after placebo
Number of subjects: 19
Study 3389864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone treatment
Number of subjects: 19
Study 3389864 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 31199462 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (0.3 mg/kg, twice a day for 2 weeks)
Number of subjects: 40
Study 31199462 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 28196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 114
Study 28196787 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhibitory training)
Number of subjects: 114
Study 28196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer‐NoGo (inhibit responses linked to task‐irrelevant pictures of beer)
Number of subjects: 114
Study 28196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained‐Stop (requiring more urgent inhibition but without pictures of beer)
Number of subjects: 114
Study 28196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (urgent inhibition to pictures of beer)
Number of subjects: 114
Study 26386850 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus I epiretinal prosthesis
Number of subjects: 1
Study 23927594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynatine® FLX (500 mg per day for 60 days)
Number of subjects: 50
Study 23927594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, identical dosage for 60 days)
Number of subjects: 50
Study 22114283 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivoxel pattern analysis (MVPA) applied to fMRI data
Number of subjects: 0
Study 22114283 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA in parieto-frontal regions
Number of subjects: 0
Study 22114283 — intervention group
Group type: COMPARATOR
Intervention: MVPA compared to traditional fMRI analysis techniques
Number of subjects: 0
Study 19131065 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg)
Number of subjects: 30
Study 16702006 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at an initial dose of 0.003 mg/kg/day for 4 weeks, increased to 0.006 mg/kg/day for 4 weeks, and then to 0.012 mg/kg/day for the last 16 weeks
Number of subjects: 73
Study 16702006 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 73
Study 16702006 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 73
Study 15085496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg every 4 hours followed by oxytocin if indicated)
Number of subjects: 162
Study 15085496 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley catheter with simultaneous use of oxytocin
Number of subjects: 162
Study 15085496 — intervention group
Group type: COMPARATOR
Intervention: Foley/oxytocin
Number of subjects: 162
Study 15085496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 162
Study 11322670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy discharge plan intervention
Number of subjects: 362
Study 11322670 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 362
Study 9479601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 80
Study 7947061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 70
Study 7947061 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing and compression therapy
Number of subjects: 70
Study 3115449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose for four days before admission
Number of subjects: 42